Injection device

Information

  • Patent Grant
  • 6213983
  • Patent Number
    6,213,983
  • Date Filed
    Monday, July 6, 1998
    26 years ago
  • Date Issued
    Tuesday, April 10, 2001
    23 years ago
Abstract
The invention features an injection device for injecting a liquid or semi-solid composition into a subject.
Description




BACKGROUND OF THE INVENTION




The invention relates to a device for the parenteral administration through a needle of liquid or semi-solid drug compositions wherein the needle is protected before and after the injection.




The parenteral introduction of pharmaceutically active compounds is preferred over oral dosage for many indications, e.g., where the drug to be administered would partially or totally degrade in the gastrointestinal tract, or where there is need for a rapid biological response. The need for extemporaneous preparation of such parenteral compositions is eliminated, or simplified, by the use of pre-filled administration devices in which the liquid to be injected is pre-loaded into the device (e.g., a pre-loaded syringe). Such pre-loaded devices, however, have a number of drawbacks, including the inability to preserve the asepsis or sterility of the needle, as well as the general danger of using an exposed needle. To eliminate these drawbacks, it is necessary to avoid the direct exposure of the needle with the environment both prior to and following injection.




SUMMARY OF THE INVENTION




The invention features a comparatively inexpensive injection device with a needle for parenteral injection of liquid or semi-solid drug compositions into a subject, e.g., a mammal such as a human, wherein the needle is protected both before and after the injection.




In general, the invention features an injection device including a housing, the housing having proximal and distal ends and designed to contain a liquid or semi-solid drug composition; a hollow needle, the needle affixed to the distal end of the housing and extending longitudinally within the housing; a plunger, the plunger arranged to slide within the proximal end of the housing; and a hollow sleeve, the hollow sleeve arranged to cover the needle prior to injection and arranged to retract into the housing during injection; wherein the device is designed such that when the sleeve is pressed against the subject, the sleeve retracts into the housing thereby allowing the needle to penetrate the subject, and when the plunger is forced further into the housing, the drug composition is forced from the housing through the needle and into the subject.




In one embodiment, the device is further designed such that when the drug composition is forced from the housing, the plunger forces the sleeve out of the housing to cover the needle. In a further embodiment, the housing contains the liquid or semi-solid drug composition.




In another embodiment, the device further comprises a septum plunger, the septum plunger slidably arranged within the housing between the plunger and the distal end of the housing. In a further embodiment, the device is further designed such that when the drug composition is forced from the housing, the plunger forces the septum plunger into the sleeve, and the septum plunger forces the sleeve out of the housing to cover the needle. In still a further embodiment, the housing contains the liquid or semi-solid drug composition between the plunger and the septum plunger.




In still another embodiment, the housing contains a liquid and a dry drug composition, where the device is designed to combine the liquid and the dry drug composition prior to injection.




The device can further include a releasable lock to inhibit the movement of the plunger into the housing. The device can also include a removable cap which covers the sleeve. The proximal end of the housing may have a flange and the plunger may also have a flange.




Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.











Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.




BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a partial cross-sectional view of an injection device prior to use.





FIG. 2

is a partial cross-sectional view of the injection device of

FIG. 1

during use.





FIG. 3

is a partial cross-sectional view of the device with the needle injected into a subject.





FIG. 4

is a partial cross-sectional view of the injection device being withdrawn from the subject with a drug composition remaining in the subject.





FIG. 5

is a partial cross-sectional view of the injection device following complete withdrawal of the needle from the subject.





FIG. 6

is a cross-section of the injection device through line


6





6


in FIG.


1


.





FIG. 7

is a view of the sleeve of the injection device.











DETAILED DESCRIPTION




It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limiting.





FIG. 1

shows injection device


1


including housing


10


, having a proximal end and a distal end


14




a


,


14




b


. The distal end of housing


10


has two holes


40




a


and


40




b


partially separating the two parts


14




a


and


14




b


of the distal end (as best seen in FIG.


6


). Needle


12


is attached to part


14




a


of the distal end. The housing


10


can be made from a rigid material such as glass, plastic, or metal. The needle


12


is hollow and double-ended, wherein its distal end, remaining outside housing


10


, has a point capable of piercing the skin of a subject, and its proximal end, remaining within housing


10


, is capable of piercing septum plunger


16


. On the proximal end of housing


10


is a flange


28


to assist in removal of device


1


from the subject following injection.




An sleeve


22


surrounds needle


12


so that needle


12


is not fully exposed to the environment until used. Sleeve


22


has longitudinal slots


45




a


and


45




b


along its length (see

FIG. 7

; slot


45




b


is on the back of the sleeve and is thus not shown). The two parts


14




a


and


14




b


of the distal end are joined by radially extending connecting members


42




a


and


42




b


(see FIG.


6


). Connecting members


42




a


and


42




b


, respectively, slide through slots


45




a


and


45




b


in sleeve


22


, while sleeve


22


slides through holes


40




a


and


40




b


in housing


10


. Sleeve


22


can be made of suitably rigid material, such as metal, glass, or plastic. Seal


24


covers the opening


23


of sleeve


22


to maintain the sterility of needle


12


and prevent sleeve


22


from unintentionally retracting into housing


10


through holes


40




a


and


40




b


prior to injection.




Seal


24


can be made of a thin material, such as plastic or wax, which is easily penetrated by needle


12


during injection. A similar seal can also cover slots


45




a


and


45




b


in sleeve


22


, to further protect the sterility of needle


12


.




Septum plunger


16


, contained within housing


10


, includes a bore


26


, in which needle


12


rests prior to subsequently piercing septum plunger


16


. A liquid or semi-solid composition


20


is isolated in housing


10


between the septum plunger


16


and the plunger tip


30


, attached to plunger


29


. Septum plunger


16


and plunger tip


30


may be made of non-rigid, solid material such as rubber, which allows septum plunger


16


and plunger tip


30


to slide within housing


10


but still maintain sufficient friction with the inner sides of housing


10


to seal composition


20


within housing


10


.




The proximal end of plunger


29


has a thumb flange


18


to assist in the depression of plunger


29


into housing


10


, and the distal end of plunger


29


has a longitudinal bore


27


to receive needle


12


following injection of composition


20


out and through needle


12


. Plunger


29


can be made from a rigid material, such as metal or plastic. A removable lock


25


may be placed between flange


18


and flange


28


to inhibit the further depression of plunger


29


into housing


10


after activation of device


1


, i.e., after the housing


10


is filled with a drug composition and the proximal end of the needle is pierced through septum plunger


16


. A removable cap


21


can also be used to protect both needle


12


and sleeve


22


prior to use. Both cap


21


and lock


25


can be made from suitable rigid material such as plastic, metal, or rubber.





FIG. 2

shows device


1


wherein plunger


29


has been pressed into housing


10


to activate device


1


as follows. When plunger


29


is depressed, plunger tip


30


, composition


20


, and septum plunger


16


are displaced toward the distal end of housing


10


. Septum plunger


16


is pierced at bore


26


by needle


12


. As a result, the proximal end of needle


12


is exposed to composition


20


. Device


1


is now in an activated state. Lock


25


, by contacting both flange


18


and flange


28


, inhibits the further displacement of composition


20


from housing


10


through needle


12


following activation of device


1


, i.e., composition


20


is allowed to fill needle


10


, but lock


25


inhibits significant release of composition


20


through needle


10


.





FIG. 3

shows device


1


wherein needle


12


has penetrated skin


32


of the subject being treated. As device


1


is pressed against skin


32


, sleeve


22


is retracted into housing


10


, through holes


40




a


and


40




b


, by the force of pressure against skin


32


. Needle


12


passes through sleeve


22


at opening


23


. As shown, needle


12


has penetrated through skin


32


into the subcutaneous layer


34


.





FIG. 4

shows device


1


wherein lock


25


has been removed and plunger


29


has been depressed which moves plunger tip


30


toward septum plunger


16


, thereby injecting composition


20


into subcutaneous layer


34


through needle


12


. Once composition


20


has been injected and plunger tip


30


rests against septum plunger


16


, housing


10


is moved away from skin


32


by exerting pressure against the lower part of the flange


28


while simultaneously exerting opposing pressure on flange


18


of plunger


29


. This relative movement of the plunger


29


and housing


10


causes plunger tip


30


to force septum plunger


16


against sleeve


22


as both plunger tip


30


and septum plunger


16


slide toward parts


14




a


and


14




b


of the distal end of housing


10


, which in turn forces sleeve


22


out of housing


10


through holes


40




a


and


40




b


. As plunger tip


30


and septum plunger


16


are moved toward distal end of housing


10


, needle


12


penetrates septum plunger


16


, plunger tip


30


, and enters bore


27


in plunger


29


.





FIG. 5

shows needle


12


fully withdrawn from skin


32


and sleeve


22


fully covering needle


12


. Composition


20


remains in the subcutaneous layer of the patient. As can also be seen in

FIG. 5

, the proximal end of needle


12


has been pushed through septum plunger


16


and plunger tip


30


and remains in bore


27


of plunger


29


.





FIG. 6

is a cross-sectional view of

FIG. 1

at


6





6


.

FIG. 6

shows holes


40




a


and


40




b


in housing


10


. Radially extending connecting members


42




a


and


42




b


extend through slots


45




a


and


45




b


, respectively, to connect parts


14




a


and


14




b


of the distal end. Needle


12


is fixed to central part


14




a


of the distal end, and sleeve


22


can slide through holes


40




a


and


40




b


.

FIG. 7

shows an isolated sleeve


22


having slots


45




a


and


45




b


(


45




b


is not shown but positioned directly opposite to slot


45




a


on the other side of sleeve


22


) and opening


23


. Radially extending connecting members


42




a


and


42




b


, respectively, slide through slots


45




a


and


45




b.






Composition


20


is a liquid or a viscous semi-solid composition containing a drug. The drug of composition


20


can be any drug capable of being parenterally administered as a liquid or a semi-solid. For example, the drug can be a vaccine, a peptide, a protein, or a small chemical entity. Examples of suitable drugs include insulin and heparin. For drugs which are not stable in liquids over an extended period of time, the liquid and the dry drug can be stored in separate chambers within housing


10


. The device can be designed such that the liquid and the dry drug are combined together just prior to injection.




For example, the chamber created between septum plunger


16


and plunger tip


30


(e.g., in

FIG. 1

) in housing


10


can be separated into two separate parts by a fixed wall or film that can be punctured, e.g., by pressure of the plunger


29


on the plunger tip


30


, or a puncturing means. Alternatively, the two parts of the chamber can be separated by a moving wall or septum. In this case, the top or proximal part of the chamber above the moving septum contains the liquid portion of the composition, and the distal part of the chamber contains the solid, e.g., powder, portion of the composition. When plunger


29


is pushed down, it applies pressure to the plunger tip


30


, which applies pressure to the liquid portion of the composition. This, in turn, applies pressure on the moving septum, causing it to move in a distal direction. The housing is designed with a liquid bypass (e.g., a bulge or passage in the housing wall) in a location that initially prevents passage of liquid from one part of the chamber to the other, but when the moving septum reaches a specific location, the bypass allows the liquid to pass from the top part of the chamber into the lower or proximal part of the chamber on the other side of the moving septum.




To maintain sterility, the device of the invention can be stored in a conventional blister pack prior to use.




OTHER EMBODIMENTS




It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.



Claims
  • 1. An injection device for injecting a liquid or semi-solid composition into a subject, the device comprising:a hollow housing having a proximal end and distal end, said housing being configured to contain a liquid or semi-solid composition; a hollow needle, said needle affixed to the distal end of the housing and extending longitudinally within said housing; a plunger arranged to slide within the proximal end of the housing; and a hollow sleeve slidably connected to the distal end of the housing and arranged to cover the needle prior to injection and to retract into the housing during injection; wherein the device is configured such that when the sleeve is pressed against the subject, the sleeve retracts into the housing thereby allowing the needle to penetrate into the subject, and when the plunger is pushed into the housing, the composition is pushed from the housing through the needle and into the subject.
  • 2. An injection device of claim 1, wherein the device is further configured such that when the composition is pushed out of the housing, the plunger moves the sleeve out of the housing to cover the needle.
  • 3. A device of claim 1, wherein the housing contains the liquid or semi-solid composition.
  • 4. A device of claim 2, wherein the housing contains the liquid or semi-solid composition.
  • 5. A device of claim 1, wherein the device further comprises a releasable lock to inhibit movement of the plunger into the housing.
  • 6. A device of claim 1, wherein the device comprises a removable cap which covers the sleeve.
  • 7. A device of claim 1, wherein the proximal end of the housing comprises a flange.
  • 8. A device of claim 1, wherein the plunger comprises a flange.
Parent Case Info

This application is a continuation of Ser. No. 08/777,634 filed Dec. 31, 1996 now U.S. Pat. No. 5,776,107.

US Referenced Citations (20)
Number Name Date Kind
3016895 Sein Jan 1962
3572335 Robinson Mar 1971
3884230 Wulff May 1975
4233975 Yerman Nov 1980
4359044 Child Nov 1982
4774091 Yamahira et al. Sep 1988
4820267 Harman Apr 1989
4846793 Leonard et al. Jul 1989
4850968 Romano Jul 1989
4994028 Leonard et al. Feb 1991
5098389 Cappucci Mar 1992
5151088 Allison et al. Sep 1992
5250026 Ehrlich et al. Oct 1993
5267972 Anderson Dec 1993
5275583 Crainich Jan 1994
5279554 Turley Jan 1994
5284479 de Jong Feb 1994
5433711 Balaban et al. Jul 1995
5487733 Caizza et al. Jan 1996
5776107 Cherif-Cheikh Jul 1998
Foreign Referenced Citations (4)
Number Date Country
0 292 936 A3 May 1988 EP
0 415 504 A1 Aug 1990 EP
1168371 Dec 1958 FR
8901124 Dec 1990 NL
Continuations (1)
Number Date Country
Parent 08/777634 Dec 1996 US
Child 09/110773 US